1. Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis

   • Brigida Anna Maiorano
   • Ugo De Giorgi
   • the MeetURO group

   Systematic Review Open access 22 November 2023 Pages: 1 - 11

   

2. Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors

   • Serafina Martella
   • Marco Maria Aiello
   • Michele Porcu

   Review Article 08 December 2023 Pages: 13 - 28

   

3. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

   • Silvia Camera
   • Margherita Rimini
   • Andrea Casadei-Gardini

   Original Research Article 22 January 2024 Pages: 29 - 39

   

4. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea

   • Yeokyeong Shin
   • Bo Hyun Moon
   • Changhoon Yoo

   Original Research Article 18 December 2023 Pages: 41 - 49

   

5. Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)

   • Hung-Ming Wang
   • Pei-Jen Lou
   • Meng-Che Hsieh

   Original Research Article Open access 29 January 2024 Pages: 51 - 58

   

6. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer

   • Yu Sunakawa
   • Yasutoshi Kuboki
   • Takayuki Yoshino

   Original Research Article Open access 09 January 2024 Pages: 59 - 69

   

7. A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis

   • Ming-Yu Lien
   • Tzer-Zen Hwang
   • Meng-Che Hsieh

   Original Research Article 02 December 2023 Pages: 71 - 79

   

8. Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China

   • Qichen Dai
   • Kexin Feng
   • Yipeng Wang

   Original Research Article 24 January 2024 Pages: 81 - 93

   

9. Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8⁺ Lymphocyte Repopulation in Hepatocellular Carcinoma

   • Eloïne Bestion
   • Madani Rachid
   • Philippe Halfon

   Original Research Article 22 December 2023 Pages: 95 - 106

   

10. Pemigatinib: A Review in Advanced Cholangiocarcinoma

    • James E. Frampton

    Adis Drug Evaluation 11 January 2024 Pages: 107 - 114

    

11. Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma

    • Nicole L. France
    • Hannah A. Blair

    Adis Drug Evaluation Open access 18 January 2024 Pages: 115 - 123

    

12. Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

    • Xiuning Le
    • Eric Nadler
    • John Victor Heymach

    Correction Open access 09 December 2023 Pages: 125 - 125

13. Correction to: Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis

    • Brigida Anna Maiorano
    • Ugo De Giorgi
    • the MeetURO group

    Correction Open access 09 December 2023 Pages: 127 - 127

14. Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer

    • Simon Fung
    • Yahiya Y. Syed

    Correction Open access 29 November 2023 Pages: 129 - 129